Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapyAntonio Giordano, Massimo Cristofanilli, Mario Giuliano et al.|Annals of Oncology|2011Cited by 102
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.Kevin Kalinsky, Dawn L. Hershman, Erica Stringer-Reasor et al.|Journal of Clinical Oncology|2022Cited by 73
Circulating tumor cells in newly diagnosed inflammatory breast cancerMichal Mego, James M. Reuben, Antonio Giordano et al.|Breast Cancer Research|2015Cited by 45
Squamous Cell Carcinoma of the Oral Cavity in Nonsmoking Women: A New and Unusual Complication of Chemotherapy for Recurrent Ovarian Cancer?Timothy Lewis Cannon, Franco M. Muggia, Dominic W. Lai et al.|The Oncologist|2012Cited by 41
Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites.Antonio Giordano, Massimo Cristofanilli, Mario Giuliano et al.|Journal of Clinical Oncology|2010Cited by 10